NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).

A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake announced disastrous Phase 3 trial results for its only ...

Coinciding with The Asset’s 25th anniversary, the highly regarded “The Asset ESG Corporate Awards” was renamed “The Asset Corporate Sustainability Leadership Awards” this year, underscoring the ...

Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with ...

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced that Seth Lederman, M.D., Tonix’s Chief Executive ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to ...

Q3 2025 Earnings Call Transcript November 4, 2025 Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.14. Operator: Good afternoon, everyone. Thank ...

Drugmaker Bristol-Myers Squibb Co (BMY.N) will globally develop, make and sell a therapy being tested by New York's ...